← boardnext 2027-06next 2028-04
IPHYF
Innate Pharmadistress 2/10 · well-funded / low risk$1.650%today-27% from 52w high
Oncology 2
Lead: Lymphoma · est. market ~$18B (approx, global)
Revenue
pre-revenue
Liquidity
$45M
Runway
1.4 yrs
Shares 1y
0%
Price & events
-23.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+10.0%
3M
-23.4%
6M
+26.0%
1Y
-14.5%
2Y
-47.6%
5Y
-60.5%
All
Overview
- Market Cap
- $154.64M
- Enterprise Value
- $140.22M
- Volume
- 0
- 52 Week Range
- $1.31 – $2.25
- Total Shares
- 93.72M
- Float Shares
- 70.54M
- % Held by Insiders
- 20.77%
- % Held by Institutions
- 9.63%
- Beta
- 0.88
Pipeline stages · 4 programs
IPH5201, durvalumab, standard chemotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IPH4502
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IPH6501
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IPH4102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | IPH5201, durvalumab, standard chemotherapy | Non Small Cell Lung Cancer | — | recruiting |
| 2028-04 Estimated 50% readout ~2028-05-01 | Phase 1 | IPH4502 | Advanced or Metastatic Solid Tumors | — | recruiting |
| 2026-02-06 | Phase 1/2 | IPH6501 | Non Hodgkin Lymphoma | 23 | terminated |
| 2026-01-08 | Phase 2 | IPH4102 | Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | 170 | completed |
Catalyst news & presentations · 1
- 2026-09-17earningsEarningsEarnings releaseyahoo
Approved drugs (1)
- LUMOXITIMOXETUMOMAB PASUDOTOX-TDFK2018 · Prescription
Capital structure — dilution & financing
Shares out: 93,719,323 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Lymphoma
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NRIXNurix Therapeutics, Inc.$2.4B · D6
- ALLOAllogene Therapeutics, Inc.$623M · D5
- ADILADIAL PHARMACEUTICALS, INC.$6M · D6
- GMABGENMAB A/S— · D1
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-23Innate Pharma (Nasdaq: IPHA) to speak on BTIG bladder cancer panel - Stock Titan
- 2026-07-23Innate Pharma CMO to Spotlight Cancer Pipeline at BTIG Bladder Cancer Panel - TipRanks
- 2026-07-23Bladder cancer treatment panel to feature Innate Pharma CMO - Stock Titan
- 2026-07-23Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference - Business Wire
- 2026-07-21Innate Pharma Completes Enrollment in Dose Escalation of Phase 1 Study of IPH4502 - marketscreener.com
- 2026-07-21Innate Pharma Completes Phase 1 Dose Escalation Enrollment for Nectin-4 ADC IPH4502 - TipRanks
- 2026-07-21Innate Pharma's IPH4502 Reports Responses in Three Tumor Types - Stock Titan
- 2026-07-21Innate Pharma completes enrollment in IPH4502 phase 1 study - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.